Biotech has been at a low year-to-date, but traders believe the sector is going to make a comeback. » Read More
Ecstasy is becoming popular again in the European Union, with online sales and targeted marketing helping to drive the revival.
The 96-year-old surgeon credited with developing the Heimlich maneuver recently used the technique for the first time himself to save a woman.
Martin Shkreli's tweet endorsement of the Republican nominee comes as he fights criminal fraud charges.
Shares of Valeant Pharmaceuticals rose more than 9 percent Friday on reports that the company rejected a joint takeover bid earlier this year.
Thermo Fisher Scientific said it would buy FEI for about $4.2 billion to gain access to its signature electron microscopy technology.
Roche got a big boost on Friday when a clinical trial testing its new blood cancer drug Gazyva proved successful.
New medicines are increasingly targeting the genetic drivers of disease. But what if medicine could go further and correct the genetic defect itself?
Scientists are working on a new treatment for depression and PTSD: deep-brain stimulation.
An angry customer filed a class action lawsuit against Theranos in the district of Northern California, The Verge reports.
This could be a game changer for diagnosis and surgery planning.
Regulators in Missouri have raised a red flag on Aetna's $34 billion buy of Humana, calling the deal anti-competitive for the state's Medicare market.
When we think about taking medicines, we imagine popping a pill, or receiving a shot. But a new approach would leverage the body's electrical signals.
The Defense Department is helping to develop prosthetics that harness what we've learned about the brain's functions.
Proposed price increases for Obamacare plans vary widely across states, and even within states.
Imagine implanting electrodes in the hippocampus to help brain-injured patients process memories. That's what the Defense Department is attempting.
Congress needs to quit wrangling over funding to fight the Zika virus so the U.S. is prepared before mosquito season, Ron Klain said.
Shares of Sarepta Therapeutics rose more than 20 percent.
Fluctuations in blood pressure could lead to brain decline, heart attack and stroke.
Anthem CEO Joseph Swedish denies reports his firm and Cigna have been at loggerheads in their attempt to gain approval the Department of Justice for their $54 billion merger.
Obamacare plan customers should brace for sticker shock when the administration posts insurers' preliminary rate requests for 2017 this week.
Get the best of CNBC in your inbox